Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of April 2019, specifically dated April 22, 2019. The registrant is a foreign private issuer based in Jerusalem, Israel, focused on pharmaceutical development.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial disclosure is a €4 million extension to an existing financing agreement with the European Investment Bank (EIB).
Material Changes
- Financing Extension: On April 22, 2019, the company secured a €4 million extension to its 2017 financing agreement with the EIB.
- Project Support: The funds are designated to support the ongoing pivotal Phase 3 clinical trial of the company's M-001 Universal Influenza Vaccine candidate.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the financing extension. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the context of the clinical trial funding. The document incorporates a press release (Exhibit 99.1) by reference for further details.
Investor Verification Checklist
- Verify the terms and conditions of the €4 million EIB financing extension.
- Confirm the current status and timeline of the M-001 Phase 3 clinical trial.
- Review the attached press release (Exhibit 99.1) for additional details on the funding structure.
- Note that this filing contains no audited financial statements or comprehensive liquidity data.